• Lexaria Bioscience is a global innovator in drug delivery platforms whose patented DehydraTECH(TM) technology has demonstrated the ability to improve the bioavailability and increase the speed of onset of many drugs
• In calendar 2022, the company achieved a number of milestones in various areas, including research programs, receipt of patents, and licensing agreements
• Lexaria started and completed its fourth and most comprehensive hypertension study yet, investigating the capabilities of DehydraTECH-CBD, with the study showing that its formulation resulted in a sustained reduction in blood pressure over the study period (five weeks)
• The company has also started investigating DehydraTECH-CBD as a potential therapeutic for the treatment of dementia and diabetes and is planning to begin another study on DehydraTECH-nicotine pouch performance
• Over the course of the year, Lexaria was granted four new patents, and entered into separate licensing agreements with four new partners

In his concluding remarks in this year’s letter to shareholders published January, Lexaria Bioscience (NASDAQ: LEXX) CEO Chris Bunka underlined that “Management of [the company] feels we are on track, on schedule, and on budget to deliver what we hope and expect will be great results in 2022” (https://ibn.fm/cD2BJ). Since then, the company has achieved crucial milestones that can well be described as “great results,” and rightly so. These milestones are centered around Lexaria’s patented DehydraTECH(TM) drug delivery technology.

DehydraTECH can be applied to many drugs and fat-soluble active pharmaceutical ingredients (“APIs”), with the resultant formulation boasting better speed of onset, bioavailability, and brain absorption. So far, Lexaria has evidenced, through pharmacokinetic (“PK”) studies, that its technology delivers higher quantities of cannabidiol (“CBD”), oral nicotine, and antiviral drugs into the bloodstream in less time, properties that are technically known as increased bioavailability.

For Lexaria, however, the end goal does not only lie in uncovering DehydraTECH’s ability to improve the bioavailability of various APIs. Instead, the company is keen on establishing whether DehydraTECH can be applied broadly within the pharmaceutical industry. And calendar 2022 has brought the company closer to realizing this goal, with the company initiating a slew of research programs, many of which it has already completed. Moreover, its intellectual property (“IP”) portfolio has received additional patent protection in different jurisdictions around the world. Lexaria has also entered into multiple manufacturing and/or licensing agreements with global partners.

Research Programs

DehydraTECH-Processed PDE5 Inhibitor

Lexaria kicked the year off with an announcement of ground-breaking findings in an animal study evaluating DehydraTECH-processed sildenafil, a phosphodiesterase (“PDE5”) inhibitor used in the management of erectile dysfunction. The study, whose results were announced February 2, showed that the DehydraTECH formulation delivered more sildenafil (roughly 70% more drug) and at a faster rate (about 25% faster) than the concentration-matched, generic control formulation (https://ibn.fm/fSxz3).

DehydraTECH-Processed CBD

In 2022, much like in 2021, Lexaria’s biggest area of investigation was CBD – or, more specifically, DehydraTECH-processed CBD. The company expanded the scope of its research to include not only investigations on hypertension or high blood pressure, a condition on which it had completed two human studies (HYPER-H21-1 and HYPER-H21-2) the year prior, but also diabetes, seizures, and dementia.

Building on the HYPER-H21-1 study, a 24-person study that evidenced a rapid and sustained drop in blood pressure, and HYPER-H21-2, which showed that DehydraTECH-CBD caused a 23% average reduction in overnight blood pressure and reduced arterial stiffness, Lexaria also released the findings of its 16-person HYPER-H21-3 study in April this year. This third study evidenced that the pulmonary artery systolic pressure was attenuated by about 5 mmHg or 41% overall in male participants (https://ibn.fm/6DBAM).

The positive findings from the HYPER-H21-3 study set the stage for the commencement of the fourth human clinical study (“HCS”), HYPER-H21-4, the most comprehensive study Lexaria has ever undertaken, that same month (https://ibn.fm/7179M). A 66-person randomized, double-blinded, placebo-controlled, cross-over study, HYPER-H21-4 was designed as a multi-week study whose dosing was completed in July with no serious adverse events reported. That was a vital outcome given that the main objective of most FDA-registered Phase I studies is to prove safety and tolerability.

This news was a precursor to even more positive news reported in late October when Lexaria announced that HYPER-H21-4 “may be the world’s first study to evidence a sustained drop in blood pressure (“BP”) in normally active hypertensive patients following multiple weeks of oral CBD therapy, using Lexaria’s patented DehydraTECH-CBD capsule formulation.”

The study showed a significant BP reduction by 2.5 weeks, with this attenuation sustained over the entire five weeks of dosing. Moreover, Lexaria also observed that the decreases in BP were similar in persons receiving treatment with standard-of-care BP medication as in persons who were not undergoing any current treatment, suggesting DehydraTECH-CBD’s potential abilities to offer additive BP reduction benefits above and beyond the therapeutic improvements of standard BP medication. This can have important regulatory implications.

“That we were able to lower blood pressure in our patient population over multiple weeks using DehydraTECH-CBD is an exceptional discovery, given that previous studies by others using other oral CBD formulations have failed to evidence this sustained benefit,” Chris Bunka commented. “DehydraTECH also demonstrated excellent safety and tolerability results and no adverse changes in liver enzymes throughout the study. Indeed, of the handful of minor, non-serious adverse events reported, there were nearly as many reported by those patients receiving placebo as those who received DehydraTECH-CBD.”

HYPER-H21-4 was designed to enhance Lexaria’s probability of success with its expected Investigational New Drug (“IND”) application to seek the US Food and Drug Administration (“FDA”) approval to begin registered clinical testing. Against the backdrop of the findings from this study, and having already received positive feedback from a pre-IND meeting with the FDA, according to an August press release (https://ibn.fm/OQl3x), Lexaria is on track to file the full IND application in 2023. (Following the pre-IND meeting, the FDA confirmed its support for an abbreviated approval pathway in line with section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.)

Meanwhile, in a separate three-part animal study that kicked off in March that aimed to assess the effectiveness of DehydraTECH-CBD in reducing seizure activity compared to the FDA-approved seizure medication Epidiolex (https://ibn.fm/X6zl1), Lexaria evidenced that DehydraTECH-CBD can be more efficacious at lower doses than Epidiolex. Additionally, the company observed that DehydraTECH-CBD can act more rapidly than Epidiolex. According to Lexaria, work is ongoing to complete the third and final part of the study that intends to establish the dose required to achieve seizure inhibition in 50% of the animals tested or ED50 (https://ibn.fm/hOsRb).

In addition to the hypertension and seizure studies, Lexaria recently commenced separate investigations on the potential therapeutic use of DehydraTECH-CBD in both diabetes and dementia. Dubbed DIAB-A22-1, the study investigating  DehydraTECH-CBD’s potential utility in the treatment of diabetes kicked off on November 8 (https://ibn.fm/V45Lm), while DEM-A22-1, the study on the potential use of DehydraTECH-CBD in dementia, begun a couple of days later on November 10 (https://ibn.fm/xp2mS).

DehydraTECH-Processed Nicotine

Calendar 2022 also marked the year when Lexaria began expanding its research on nicotine to include human subjects. Having resolved the manufacturing and logistics challenges that had previously pushed back the commencement time as well as having received Independent Review Board (“IRB”) approval for the planned human oral nicotine study, NIC-H22-1, Lexaria expects to begin dosing in December 2022 (https://ibn.fm/6L0fJ).

A 36-person human PK, randomized, double-blinded, cross-over-study carried out in current cigarette smokers, NIC-H22-1 will see each participant receiving only one brand of oral nicotine pouch on each of the three visits to the laboratory over a period of weeks. Upon administration, each person will undergo both subjective and objective evaluations, with vital signs such as respiratory rate, heart rate, blood pressure, and temperature also collected. Overall, the study is specifically designed to compare the performance of Lexaria’s DehydraTECH-nicotine pouch to On!’s (a pouch brand manufactured by Altria) and Zyn’s (the world’s leading nicotine pouch product manufactured by Swedish Match).

Competition in the nicotine pouch category is heating up, with PMI have just completed its US$16 billion acquisition of Swedish Match.

Previously, Lexaria had demonstrated in animal study NIC-A21-1 that oral nicotine pouches processed using DehydraTECH were 10 to 20 times faster in reaching peak delivery of nicotine to the bloodstream than controls.

Patents

In 2022, Lexaria continued to strengthen its intellectual property portfolio, receiving four new patents as described below:

• In March, Australia granted Lexaria a patent entitled “Compositions Infused with Nicotine Compounds and Methods to Use Thereof” that covers most oral forms of nicotine, including sprays, gums, pouches, capsules, lozenges, tablets, and pills. The patent also covers various forms of nicotine, including free base nicotine, polymer resins of nicotine, nicotine salts, and other forms of nicotine complexes (https://ibn.fm/o9j34).
• In April, the United States Patents and Trademark Office (“USPTO”) granted Lexaria its first-ever patent for using DehydraTECH technology to enhance the delivery of antiviral drugs (https://ibn.fm/GVR4X).
• In July, Lexaria received its fourth patent granted in Japan, entitled “Lipophilic Active Agent Infused Compositions with Reduced Food Effect,” which acknowledges the ability of DehydraTECH to deliver APIs more effectively regardless of the presence of foods within the gastrointestinal system (https://ibn.fm/B7VuC).
• In August Lexaria received a new patent in Mexico that covers multiple claims, including but not limited to the treatment of hypertension, neurological diseases, diabetes, hepatic diseases, and more (https://ibn.fm/7RM1Q).

With the receipt of the four patents in 2022, Lexaria now has 27 worldwide patents granted, with about 50 more patents pending worldwide. The company believes that should the remaining patent applications become granted patents, its ability to generate meaningful license revenue from its IP may increase from multiple other countries and regions outside of the United States. And if this year’s licensing agreements are anything to go by, Lexaria is progressively inching closer to this goal, one partner at a time.

Licensing Agreements

Generally, the company’s granted patents help to buttress a part of the company’s business plan, which according to its latest annual report, is to “encourage new and existing participants to license and utilize DehydraTECH to enable enhanced performance of their products” (https://ibn.fm/FzUTU). To that end, this calendar year saw the company onboard new partners who have licensed the DehydraTECH technology for use in their respective markets. Anchored in licensing agreements announced in June, the licenses include:

• A European and United Kingdom DehydraTECH license for medical cannabis applications from wholly owned subsidiary Lexaria Pharmaceutical Corp. to Valcon Medical A/S, a European contract manufacturing organization (“CMO”) that manufactures medical cannabis extracts for the European Union (“EU”) and the UK (https://ibn.fm/ciTUJ)
• An exclusive commercial licensing agreement granted to Premier Wellness Science Co. Ltd. for the Japanese non-pharmaceutical market for the use of DehydraTECH with CBD and hemp ingredients in oral liquid and non-liquid products, topical, hair, lip-care, and cosmetics products (https://ibn.fm/0f8D0)
• A five-year, non-exclusive DehydraTECH license to AnodGen Bioceuticals of Ireland, a CMO, for the manufacturing and distribution of DehydraTECH-processed cannabinoid API powders within Europe, Australia, and New Zealand (https://ibn.fm/FjMBZ)
• Two agreements – a manufacturing operating agreement and a commercial license agreement – with Atlanta-based BevNology LLC. (https://ibn.fm/vEY4J)

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• SideChannel is a company making cybersecurity accessible and simple, especially for small and mid-sized businesses (“SMBs”)
• The company provides cybersecurity services in the form of virtual CISOs (“vCISOs”), engineering services that enable the vCISOs to provide operational day-to-day security and privacy to clients, and proprietary security software called Enclave
• SideChannel’s differentiator from its competition is its team of experts, and recently the company hired IT and cybersecurity veteran Sean Higgins as Principal Consultant
• In this role, Sean will help client companies’ CISOs and senior management evaluate and have greater levels of confidence in their security programs

SideChannel (OTCQB: SDCH), a company focused on making cybersecurity more accessible and simple, especially for small and mid-sized businesses (“SMBs”), recently expanded its team with the hiring of Sean Higgins as Principal Consultant (https://ibn.fm/AeZGL).

An information technology (“IT”) veteran with over 35 years of experience, almost 30 of which have been focused on cybersecurity, Sean previously worked as the Chief Technology Officer (“CTO”) and Co-Founder at Herjavec Group, a global cybersecurity product and services provider. In his Principal Consultant role at SideChannel, Sean will help SideChannel’s clients’ in-house Chief Information Security Officers (“CISOs”) and management assess and have confidence in their security programs.

Higgins’ onboarding is timely, given the prevailing cybersecurity challenges SMBs face and the ever-growing volume of threats. According to a July 2022 article in Forbes, SMBs face more hurdles than larger corporations when trying to safeguard their computing and networking infrastructure against the growing number of cyberattacks and allied threats. The drawbacks, the article notes, include a lack of resources, skills, and staff (https://ibn.fm/EeciE). And as the 2022 CISO Survey of Small Cyber Security Teams report, which was quoted in the article, established, this problem is further compounded by the fact that small security teams are often allocated small budgets. It comes as no surprise then that these teams are paying attention to fewer security alerts in 2022 than they did the previous year.

The study further documented the problems SMBs face when operating threat protection products. The biggest include having overlapping capabilities of different technologies, viewing the full picture of an attack, and deploying and maintaining disparate technologies on one machine. Moreover, the report ranked the lack of skilled security personnel as the top barrier to maintaining security posture. Other barriers include excessive manual data analysis, a remote workforce, ineffective user awareness training, and a lack of budget.

With the U.S. Cybersecurity and Infrastructure Security Agency (“CISA”) warning of imminent cyberattacks in the wake of Russia’s invasion of Ukraine (https://ibn.fm/uMIXf), SideChannel is positioning itself as the cybersecurity company whose products and services are designed to help SMBs get around the existing challenges. SDCH specifically provides cybersecurity services in the form of virtual CISOs (“vCISOs”), engineering services that enable the vCISOs to provide day-to-day operational security and privacy to clients, and proprietary security software called Enclave. Enclave allows organizations to micro-segment their corporate networks, thus preventing network-wide access by hackers in the event of an attack.

In a presentation delivered during the Windy City Roundup 2022 Conference held in October, SideChannel CTO and Co-Founder Nick Hnatiw explained why the company offers vCISO services. (A recording of the webcast is available upon registration at https://ibn.fm/TCOY1. CISOs, Nick began, implement and create strategy documents that guide the security of organizations. These documents detail how to protect the company from cyber threats and ensure compliance with regulations.

“SideChannel has discovered that all organizations need to have a CISO, but they all cannot afford one,” Nick underlined the gap in the market. To further emphasize this point, a fall 2021 study, entitled The State of Cybersecurity Leadership and Readiness, found that 45% of companies do not employ a CISO. In addition, 60% of the companies delegate the role of developing their cybersecurity strategies was to IT and compliance teams or even the executive leadership rather than to dedicated CISOs (https://ibn.fm/M8EPb).

With the aforementioned 2022 study having already cited budget constraints as one of the hurdles to implementing cybersecurity programs or hiring personnel with the requisite skills, SideChannel is filling an existing gap. The idea behind providing vCISO services, Nick noted, “is to fractionalize the time of the CISO and distribute it to many organizations.” SideChannel matches companies with an expert vCISO so the organization can assess cyber risk and ensure cybersecurity compliance.

“Our differentiator to our competition is our people. SideChannel is the leading cybersecurity firm with a growing list of former enterprise-level CISOs to deliver vCISO services to clients,” SideChannel’s website reads.

For more information, visit the company’s website at www.SideChannel.com.

NOTE TO INVESTORS: The latest news and updates relating to SDCH are available in the company’s newsroom at https://ibn.fm/SDCH

• The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications
• The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more
• The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025

A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid can reduce hospitalization and death among high-risk COVID-19 patients, there are situations where it is not recommended due to ritonavir’s ability to increase concentrations of drugs that strongly depend on hepatic cytochrome P-450 3A metabolism. The study further supports the argument and necessity for radically improved COVID-19 treatments (https://ibn.fm/h26qS). BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on the development, manufacturing, and commercialization of innovative immunotherapeutic products primarily treating infectious and autoimmune diseases, announced statistically significant (p<0.001) efficacy results in a preclinical in-vivo proof-of-concept study of its innovative inhaled nanosized antibody (NanoAb) COVID-19 therapy (https://ibn.fm/j25pD). BiondVax is developing a pipeline of alpaca-derived NanoAb therapies to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, psoriatic arthritis, and macular degeneration. Compared with current monoclonal antibodies (“mAbs”) treatments, BiondVax’s NanoAbs exhibit strong potential for superior patient convenience, safety, and clinical outcomes, at a lower cost. BiondVax’s study was designed using an industry-standard animal model for COVID-19 therapeutics and vaccines and compared weight loss in two groups of hamsters after infection with SARS-COV-2. The experimental group was treated with the company’s anti-COVID-19 NanoAb, administered via inhalation, starting one day after infection. The control group was treated in the same manner but with saline as a placebo. These studies were conducted by The Fraunhofer Institute for Toxicology and Experimental Medicine (“ITEM”) and The University of Veterinary Medicine Hannover (“TiHo”), Germany, two world-renowned institutions. The study concluded that compared to pre-infection weight, the control group’s weight declined on average at 12.01%. In contrast, on average the weight of the experimental group using BiondVax’s NanoAb therapy declined only 3.80%. The successful result of the study was further supported by eight other tracked parameters, including heart rate and social behaviors, indicating that the group treated with NanoAbs experienced a milder, shorter illness. According to Research and Markets, the global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025. A key factor driving the therapy market’s growth is the fact that social restrictions in place during the pandemic have generally eased, and preventative vaccine and booster uptake is waning, with an expected consequence of more COVID infections requiring treatment. (https://ibn.fm/lx8iz). “We are excited that the study results confirm the inhalation concept of our exclusively licensed NanoAb as a therapy for COVID-19 illness,” said BiondVax’s Chief Science Officer (“CSO”), Dr. Tamar Ben-Yedidia Ph.D. “Following these promising results, we intend to continue the study early next year by testing additional dose levels of the inhaled NanoAb therapy and as a prophylactic (preventive) treatment. Results of the trial will inform design of the first-in-human clinical trial of the inhaled NanoAb COVID-19 therapy, which is planned for late 2023.” For more information, visit the company’s website at www.BiondVax.com. NOTE TO INVESTORS: The latest news and updates relating to BVXV are available in the company’s newsroom at https://ibn.fm/BVXV

• Marijuana sales are projected to hit $33 billion in 2022, up from $3 billion in 2015, and are on track to hit $53 billion by 2026
• REZYFi, a growth mortgage origination and specialized financing company, with target markets including the legalized cannabis industry, is set to be one of the key beneficiaries in this anticipated growth
• With the ongoing conversation around marijuana, along with the bipartisan support for its legalization, the company is optimistic that the demand for its products and services will see a spike as time progresses
• REZYFi still believes that financing options for cannabis-related firms will continue to be scarce, despite progress in marijuana legalization, presenting an opportunity for the company

Back in 2017, marijuana sales were valued at $9 billion. By the end of 2022, sales are projected to hit $33 billion, posting a 20% growth. The sector is also on track to hit $53 billion in sales by 2026 (https://ibn.fm/uAE7p). REZYFi, a growth mortgage origination and specialized financing company based in the United States, is set to be one of the key beneficiaries of this anticipated growth. Given its focus on licensed and permitted cannabis companies, owners of real estate who lease to cannabis companies, along with companies and individual homeowners seeking a variety of real estate-related and additional mortgage-based financing, the growth of the marijuana sector is bound to come with expanded market opportunities for the company. For the longest time, cannabis-related businesses and companies have struggled to obtain financing from traditional banks. Federal law has forced traditional banks to shun such businesses, given that marijuana use is criminalized. However, with the ongoing conversation around marijuana, along with the bipartisan support for its legalization, REZYFi is optimistic that the demand for its products and services will see a spike as time progresses. “REZYFi believes the demand for innovative financing offerings by players in the cannabis market will continue to grow as more geographic markets legalize recreational and medical cannabis usage, a belief that has fueled its expansion within the United States,” notes a recent article (https://ibn.fm/ysCHh). Despite progress in the legalization of marijuana, REZYFi still believes that financing options for cannabis-related firms will continue to be scarce, as traditional banks are slow to adapt to the changing environment. As a result, it reckons that these entities will continue to experience difficulties obtaining financing from these traditional sources, which, while a downside on the businesses’ part, is an opportunity for REZYFi. So far, REZYFi is licensed in 36 states, with plans to expand into additional jurisdictions, hopefully within the coming year. With President Biden set to sign the first official stand-alone piece of marijuana legislation this month, the company anticipates a bump in demand for its offerings. In addition, the proliferating bipartisan marijuana legislation, coupled with the growing public support, highlights encouraging long-term momentum for the entire marijuana industry, which will be integral to REZYFi’s growth. For more information, visit the company’s website at www.REZYFi.com. NOTE TO INVESTORS: The latest news and updates relating to REZYFi are available in the company’s newsroom at https://ibn.fm/REZY

• Residential solar power installations posted a 34% growth from 2.9 gigawatts in 2020 to 3.9 gigawatts in 2021. In addition, 17.6 gigawatts of new utility-scale solar capacity came online between June 2021 and June 2022
• This growth has been linked to the falling cost of solar power infrastructure, with solar PV posting a 70% drop since 2014
• Correlate has seen a notable spike in demand for its products and services in recent months and is currently executing a $200 million project pipeline
• Through its finance platform, the company is making proprietary technology available to interested parties, and through its unique data-driven approach powered by proprietary analytics, it is helping tailor renewable energy solutions specific to customer needs
• Correlate is helping make renewable energy affordable and accessible, to help the country spur economic growth without sacrificing the environment

Over 30 countries worldwide have achieved “absolute decoupling,” with 25 pulling off this incredible feat over the past few decades. Absolute decoupling entails figuring out how to reduce carbon emissions while continuing to grow economically. One major contributing factor to this achievement is the move from fossil fuel to renewable alternatives such as solar, wind, geothermal, and bioenergy, among others (https://ibn.fm/wfNTs). Correlate Infrastructure Partners (OTCQB: CIPI), a tech-enabled development, finance, and fulfillment platform for distributed energy solutions across North America, believes in the potential of solar energy and the value it holds for aiding the United States to achieve absolute decoupling. Its understanding of the market and the renewable energy sector has allowed it to focus on providing solar energy infrastructure and maintenance services, electric vehicle infrastructure, and intelligent efficiency retrofits for community-scale applications. These aspects have earned it a unique value proposition and a significant competitive advantage in the North American market. Correlate has seen a notable spike in demand for its products and services in recent months and is currently executing a $200 million project pipeline. This growth reflects an overall increase in the rate of solar power adoption in the United States, with residential installation posting a 34% growth from 2.9 gigawatts in 2020 to 3.9 gigawatts in 2021, according to the U.S. Energy Information Administration (“EIA”) (https://ibn.fm/O9lcV). In addition, 17.6 gigawatts of new utility-scale solar capacity came online from June 2021 to June 2022, bringing utility-scale solar capacity to 65.8 gigawatts (https://ibn.fm/L3llQ). The increase in solar power adoption has been linked to the falling cost of solar power infrastructure, with solar photovoltaics (“PV”) posting a 70% drop since 2014 (https://ibn.fm/eMCbD). On November 30, 2022, Correlate announced a 3.8-megawatt solar energy installation project with EnerSys (NYSE: ENS), a global leader in stored energy solutions, at their global headquarters in Pennsylvania, making it one of the largest behind-the-meter solar installations in the United States. The project was a critical addition to Correlate’s portfolio while also playing a pivotal role in showing the demand for the company’s distributed energy solutions and the value associated with solar power. In addition, it aids Pennsylvania Governor Tom Wolf in his goal to bring statewide green energy power usage to at least 40%, in a move that seeks to achieve a 26% drop in greenhouse gas emissions by 2025. “This partnership and project bring together a decade of our team’s vision, whereby we are both supporting a corporate renewables program and helping decarbonize the supply chain with a global market leader,” noted Todd Michaels, Correlate’s CEO. “We’re proud to be working with EnerSys to further advance solar development in the Commonwealth and to support their commitment to long-term sustainability as an industry leader,” he added (https://ibn.fm/0zybr). With absolute decoupling heavily dependent on the affordability and availability of clean energy technology, Correlate is aggressive in its push to make this a reality. Through its finance platform, it is making proprietary technology available to interested parties. Additionally, through its unique data-driven approach powered by proprietary analytics, it is helping tailor renewable energy solutions specific to customer needs, aiding in its adoption and an overall transition from reliance on fossil fuels. EnerSys is a testament to Correlate’s meticulous approach to solar power installation and maintenance. It is also indicative of the company’s capabilities, it’s understanding of the industry, and its belief in the potential of solar power to help countries achieve economic growth without sacrificing the environment. The project also reflects Correlate’s commitment to creating value for its shareholders and pushing the envelope regarding innovation and service delivery. For company information, visit the company’s website at www.CorrelateInfra.com, including the following:

• Breaking Down Barriers To Your ESG Goals While Generating Additional Net Operating Income: www.CorrelateInfra.com/our-process
• Platform Generates New Rent And Operating Income, Allowing You To Meet Your ESG Goals: www.CorrelateInfra.com/program

NOTE TO INVESTORS: The latest news and updates relating to CIPI are available in the company’s newsroom at https://ibn.fm/CIPI

• Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment
• CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels
• CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe
• Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan Drug status

The most common primary brain cancer in adults and one of the most aggressive, glioblastoma, remains a critical unmet medical need because of its level of morbidity and the lack of effective treatment options nearly a century after it was defined by pioneering neurosurgeons Percival Bailey and Harvey Cushing in 1926. Glioblastoma, known simply as GBM, is effectively 100 percent fatal with extremely rare, noteworthy exceptions. The brain cancer is diagnosed in approximately 13,000 U.S. patients and only 10 percent or less of them survive to five years, most succumbing within about a year (https://ibn.fm/epCgQ). Biopharmaceutical innovator CNS Pharmaceuticals (NASDAQ: CNSP) is enrolling patients in the United States and Europe for its potentially pivotal global clinical trial in humans for its lead drug candidate designed to treat GBM. The drug, Berubicin, is an anthracycline chemotherapy agent that apparently has the unique ability to cross the blood-brain barrier to target tumors directly. The inability of anthracyclines to cross the blood-brain barrier has been identified as a major obstacle in treating aggressive brain tumors such as GBM and creates an opportunity for CNS Pharmaceuticals. “Anthracyclines are designed to damage the DNA in cancer cells,” CEO John Climaco said during a 2020 webinar about the potentially pivotal global trial (https://ibn.fm/6WbPd). “Anthracyclines as a class of chemotherapy have been used for over 60 years to treat a variety of cancers, including breast, ovarian, lung, lymphoma and leukemia, and other malignancies as well. However, historically, anthracyclines have never been used to treat primary or metastatic brain cancers because scientists could not demonstrate that anthracyclines were able to cross the blood-brain barrier and achieve significant levels of activity in the brain. Berubicin may change that history.” A Nov. 14 news release provided a corporate update, noting that 68 clinical sites have now been identified in the United States, Italy, France, Spain, and Switzerland with 29 of them currently enrolling patients (https://ibn.fm/AtOme). The news release shows several sites have been added even since the U.S. National Library of Medicine’s clinical trials registry was updated earlier this month. The majority of the recruiting sites are located in the United States, spread from California to New York, with sites in France the most recent to begin enrolling patients (https://ibn.fm/xulW0). The company is taking a phased approach to funding the worldwide complex trial, with current funding sufficient for operations into next year. During the corporate webinar, Chief Medical Officer Dr. Sandra Silberman said up to 243 patients will participate in the trial, 162 of them receiving Berubicin and the other 81 receiving the chemotherapy drug lomustine. “We are evaluating responses defined as a decrease in the size of the tumor, as well as stability of the disease defined as no further increases in the size of the tumor once the patient is put on study, as well as the time to progression of these tumors and importantly overall survival of the patients,” Silberman said. Radiation and surgical removal can significantly improve overall survival (“OS”) of GBM patients but because of the tumor’s growth from critical brain tissue, it is generally impossible to completely remove the tumor without harming the patient so the cancer tends to recur. With recurrent GBM, medical intervention has been able to improve progression-free survival (“PFS”) for a few months but not OS, according to a recent report published in Oncology Nursing News (https://ibn.fm/kXguz). Research presented in a poster at November’s 27th Annual Meeting of the Society for Neuro-Oncology compared treatment efficacy and patient characteristics in phase 3 trials of adults newly diagnosed with glioblastoma between 2005 and 2021, and identified 11 trials of 100-plus patients with OS as an endpoint, of which only three reported an OS benefit ranging between medians of 12 and 48 months (https://ibn.fm/PD0wZ). Berubicin appeared on the scene as a potential outlier in 2006 when a small safety trial conducted by its original developer, Reata Pharmaceuticals, resulted in one of the two dozen evaluated patients emerging cancer-free, remaining so over the years since, while nearly half of the trial’s other patients experienced a statistically significant improvement in clinical benefit (https://ibn.fm/Ngg2z). CNS entered a collaboration agreement with Reata after its founding in 2017, leading to the current effort to establish Berubicin’s effectiveness and take it to market. For more information, visit the company’s website at www.CNSPharma.com. NOTE TO INVESTORS: The latest news and updates relating to CNSP are available in the company’s newsroom at https://ibn.fm/CNSP

• Autonomous robotics are increasingly being used to automate manual logistics processes
• In addition to its own software solutions, Cepton collaborates with software provider Exwayz to present a robotic solution for global customers
• The company recently announced that it will unveil its upcoming next-generation automotive lidar solution, the Vista-X120 Plus, at the forthcoming CES 2023 event in Las Vegas
• As part of that product launch, Cepton has been recently recognized as a 2023 Innovation Award honoree by CES within the vehicle tech and advanced mobility category

In early June, Amazon unveiled its new fleet of autonomous robots, designed to revolutionize the way that half a million warehouse workers interact on a daily basis. Nicknamed ‘Proteus’, these robots would help automate the movement of large and heavy rolling carts of packages, creating a more efficient and safe process. These actions are traditionally undertaken by workers obliged to manually handle goods through areas where existing robots can’t go. Whilst the technology is part of a long-awaited wave of automation designed to improve productivity and boost safety standards within the logistics industry, it may not have been possible without the employment of the humble lidar sensor (https://ibn.fm/8hpG0). Although the first presentation of lidar sensors began in the 1960s, it would take until the Apollo 15 mission in 1971 for lidar to become “mainstream” with the technology being used to help map planetary surfaces. Half a century later, Cepton (NASDAQ: CPTN), a Silicon Valley innovator and leader in high-performance lidar solutions, has gained widespread renown across the industry for both its comprehensive lidar-based solution platform as well as its unique approach which focuses on performance, cost, and reliability. In early November, Cepton announced that it would be further broadening its technological reach by collaborating with Exwayz to develop novel lidar-based perception solutions for mobile robotics applications. Exwayz is a developer of plug-and-play perception software designed to help enable lidar-based 3D mapping, localization, and re-localization as well as object detection and classification. Similar to Amazon’s Proteus robot fleet, the venture’s lidar based solution will provide high-precision 3D data, which can help robotic systems navigate safely and autonomously while enabling operators to easily track their locations, gaining critical insights into how a space is being utilized (https://ibn.fm/NyERI). Cepton offers a full suite of lidar sensors for automotive and smart infrastructure applications, as well as proprietary perception solutions. Cepton’s collaboration with Exwayz further unlocks the potential utilization of its lidar technology across a wide range of mobile robotics applications. By leveraging the versatility and reliability of Cepton’s high-performance, easy-to-integrate lidars, Cepton and Exwayz aim to provide an immediate solution to expediting solution integration processes for global customers Henri Häfner, Director Product Management, Marketing and Business Development at Cepton, commented in regard to the tie-up: “Cepton’s automotive-grade lidar sensors have demonstrated the quality and reliability necessary for mobile robotics solutions. Our core lidar technology enables an optimal combination of high performance, ruggedness, and unrivalled embeddability. We are now pleased to be working with Exwayz to also deploy Cepton’s award-winning Nova Lidar for near-range applications.” The positive sentiment was mirrored by Mathias Corsia, CTO and Co-Founder at Exwayz, “We have been working with Cepton since the first day we released our product in October 2021. In addition to the impressive range and level of details measured by their sensors, we were very impressed by the compactness and variety of Cepton’s product line, which fits perfectly the industry needs in terms of integration and robustness for making autonomous systems a reality.” Although the tie-up with Exwayz as well as the expanded presence for Cepton, the company recently revealed that its core automotive offering had simultaneously been upgraded – with Cepton recently recognized for its next-generation automotive lidar product, Vista®-X120 Plus, in the prestigious CES Innovation Award program as a 2023 honoree in the Vehicle Tech & Advanced Mobility category. The Vista-X120 Plus is set to feature an unprecedented combination of ultra slim and small form factor, top-end performance, and real-time adaptive 3D perception. The Vista-X120 Plus will be unveiled by Cepton in January 2023 at the CES 2023 conference. “I am thrilled that Cepton’s innovative technology continues to be recognized at a global level and at events such as CES,” said Cepton’s Co-Founder and CEO, Dr. Jun Pei (https://ibn.fm/S9Mme). “Vista-X120 Plus is designed for both today’s consumer vehicles as well as the next generation – intelligent, electrified and software-defined. As the automotive industry evolves, our lidar innovations never cease to advance. This new product is an extension of Cepton’s vision since 2016, which is building capable, reliable and affordable lidar solutions to enable safe and autonomous transportation for everyone.” For more information, visit the company’s website at www.Cepton.com. NOTE TO INVESTORS: The latest news and updates relating to CPTN are available in the company’s newsroom at https://ibn.fm/CPTN

Web3, Crypto, and blockchain traders, investors, enthusiasts, and professionals are invited to attend Quantum Miami – a Web3 & Blockchain conference being held on January 25-27, 2023, at the James L Knight Center in Miami, Florida. Join the mammoth networking channels and leverage the immense business and growth potential this platform offers.

Industry stalwarts who have proven their mettle in these innovative and evolving ecosystems will bring their expertise to Quantum Miami. Aspiring businesses and professionals of the crypto and blockchain spectrum can avail the immense opportunity presented at Quantum Miami. Unleash new ideas and learn from the experiences of these industry leaders to shape your business destiny.

The event will witness an impressive line of speakers – dignitaries, thought leaders, and pioneers, all sharing their journeys of how they ventured into the unknown territories of crypto, Web3, and blockchain, and successfully carved their niche. Engage with industry leaders, participate in engaging panel discussions, and get your queries addressed by the industry masters themselves.

Quantum Miami offers an interactive floor where attendees will discuss and share important topics on the latest news, trends, and the future of these technologies. Experts will offer their valuable guidance through panel discussions, keynote speaker sessions, chats, and other interactive sessions. Companies can showcase their innovative and novel technologies to get visibility among the industry’s best and potential investors visiting the conference.

At the conference, attendees will witness:

• Learn about the new investment models that will lead the future of the industry. Investors can accumulate vast knowledge of crypto-winter-proof strategies so that they can move ahead with confidence
• As an evolving industry, new laws and tax regulations directly affect businesses. Stay abreast with the latest announcement in the sphere of taxes and laws by experts who will share insights on what’s trending in the industry right now
• These technologies have created a breakthrough where a whole new industry has emerged and governing policies have been updated in accordance. The industry leaders will share a wealth of knowledge on how to take your investments, wealth, and business to a whole new level

Quantum Miami is being organized by some of the same team as “The North American Bitcoin Conference 2022” and “Fantom DC,”. These industry veterans have launched several pioneer industries and facilitated mammoth investments from the connections made at their events.

To learn more, please visit https://ibn.fm/Q6yPi

• Homes in the US are increasingly resorting to electricity to satisfy their power requirements, shifting away from their prior mixed-fuel use model
• All electric homes can result in carbon emissions which are 81% lower than their mixed-fuel counterparts whilst simultaneously, resulting in significant utility-related cost savings
• GeoSolar Technologies have sought to cater to the ongoing electrification of US households through their proprietary SmartGreen(TM) Home system
• A recent housing development in Riverside County, California has looked to test the dual concepts of green energy powered households and a microgrid – insulating homes within the community from failures in the state power grid

If you were to acquire a home constructed at any point over the past forty years, chances are that it is an all-electric home. A survey carried out by the US Energy Information Administration found that 35% of hom es built in 1980 or later used only electricity, with 25% of all homes nationwide now solely employing electricity to satisfy their power requirements (https://ibn.fm/lQwWS). A recently published research study has now revealed that not only do all-electric homes result in substantial carbon emissions savings over their mixed-fuel powered counterparts – over 81% lower on average, but they also boast a far more inexpensive cost profile. Within New York alone, an all-electric home was shown to result in net present cost savings of as much as $6,800 relative to a mixed-fuel home over the course of the 15-year study. The carbon emissions savings of an all-electric home have been warmly welcomed by local state governments; cities in California, Washington, New York, and Massachusetts have all passed laws or adopted codes mandating or encouraging all-electric new building construction. Meanwhile, regional coalitions across the country are forming to extend lessons learned from these first movers to other states, including in New England and the Midwest. The desire by governmental bodies and homeowners alike to lower carbon emissions and decrease utility costs has sparked a drive towards household electrification and consequently, a transition away from the yesteryear model of mixed-fuel use households. It is exactly this kind of vision that GeoSolar Technologies (“GST”), a Colorado-based climate technology company has looked to cater to. Through the introduction of its proprietary SmartGreen(TM) Home system – an environmentally friendly, renewable energy focused technology designed to harness energy from the earth and sun to power and purify homes and automobiles without the use of fossil fuels, GeoSolar have looked to tackle the astounding thirty percent of global greenhouse gases generated by households every year. Moreover and during a time of increasingly elevated electricity costs, the company revealed that the average GeoSolar-powered home could result in a negligible carbon footprint with homeowners disbursing less than $100 per annum in utility bills (https://www.geosolarplus.com/geosolarplus). Although green energy adoption has been slow to gain mass-market appeal, the future of low-carbon, climate resilient housing is increasingly coming into view – most recently in a quiet residential community nestled within California’s Riverside County. A recent subdivision of 78 new homes in the town of Menifee were constructed in an entirely environmentally friendly manner – with electric power sourced from batteries tapping into rooftop solar panel systems and geo-thermal heat pumps providing year-round climate control. Moreover, the homes have been connected to form a microgrid, a self-contained power system that can operate independent of California’s grid in case of failure – an increasingly likely occurrence with climate-driven wildfires, heat waves and storms contributing to widespread power outages in recent years (https://ibn.fm/svueF). The federal government has seen the potential in green communities such as the one coming up in Riverside County, providing the subdivision’s contractors a $6.65 million grant to develop and test first-of-its-kind microgrid technology and determine whether the Menifee microgrid could serve as a model for future housing developments. “We want to see how we can improve resilience for the homeowner,” said Ram Narayanamurthy, emerging technologies program manager at the Energy Department. “Electrification is really going to drive carbon footprint reduction as the California grid gets more and more decarbonized.” For more information, visit the company’s website at www.GeoSolarPlus.com. NOTE TO INVESTORS: The latest news and updates relating to GeoSolar Technologies are available in the company’s newsroom at https://ibn.fm/GST

• MetAlert recently announced the signing of an LOI with Sensio Group for the marketing and distribution of RoomMate, a 3D Infrared supervision product with a fall detection automated monitoring system
• The company has set out to solve problems unique to individuals afflicted with ADA by creating devices specific to their use cases, and RoomMate is one such product, promising effective remote patient monitoring while maintaining anonymity
• Through this partnership, MetAlert looks to penetrate the high CAGR projected patient monitoring devices market, valued at $47 billion in 2021
• It also looks to leverage the partnership for future up-listing onto a major exchange such as NASDAQ
• Its management is confident that with its value proposition and unique market positioning, it will soon position MetAlert as a dominant player in its sector, commanding a significant market share and realizing substantial earnings

MetAlert (OTC: MLRT), a Los Angeles-based pioneer in location-sensitive health monitoring devices and wearable technology products, announced the signing of a Letter of Intent (“LOI”) with Sensio Group, a Norway-based provider of welfare technology and home automation solutions, for the marketing and distribution of RoomMate(TM). MetAlert hopes this partnership will initiate the promotion of this new product in the U.S., Canada, and the U.K., leveraging on Sensio’s understanding of the existing market, its brand equity, and its robust distribution network. “We are very excited about this partnership and remarkable proven technology. With over 5,500 RoomMates in operation in 220 municipalities across Norway, Sweden, Denmark, and Iceland, we will begin marketing and distributing the product and monitoring service in the U.S., Canada, and the U.K. immediately,” noted Andrew Duncan, MetAlert’s Business Development Director (https://ibn.fm/rB3tE). RoomMate, one of MetAlert’s flagship products, is a wall-mounted alert system that delivers both efficiency and privacy. It detects and alerts caregivers about patient behavior that could lead to falls and injuries, using 3D infrared and wall-mounted sensors that eliminate the need for any other physical installations or wearables. Unlike more mainstream patient monitoring systems, RoomMate does not use cameras, and the collected images are not stored. Instead, its use of infrared maintains patient anonymity, while action logs help inform caregivers of any critical information they might need to know as they provide their services. It is estimated that patients with Alzheimer’s, dementia, and autism (“ADA”) account for approximately 2.9% of the world’s population, equivalent to 34 million people in 24 developed countries. Given their unique issues, which include, but are not limited to, memory problems and adversity to wearing unknown items, traditional products such as Fitbits and iPhones do not provide a practical solution. Therefore, MetAlert has set out to solve this issue by creating devices specific to their use cases and designed to improve their overall quality of life. This commitment has birthed various offerings, including GPS SmartSoles HUB, Telehealth, Concierge, Bluetooth Enabled Devices, Artificial Intelligence Software, and Tale-Along Tracker. With RoomMate having been deployed in Los Angeles about six weeks ago, the reception has been largely positive, with the users lauding its overall effectiveness and, more importantly, how much it prioritizes privacy. “We installed RoomMate about 6 weeks ago in a private home, and both parents have told us how this product has changed their lives,” noted Patrick Bertagna, MetAlert’s CEO. “They can now monitor their autistic child’s activities remotely and unobtrusively, 24×7, without always having someone with him or a camera that would violate his privacy; it’s a game changer for them,” he added. MetAlert looks to penetrate the high CAGR projected patient monitoring devices market, valued at $47 billion in 2021, through this partnership with Sensio (https://ibn.fm/E8E49). In addition, it looks to leverage it for future up-listing onto a major exchange such as NASDAQ. Its management is confident that its value proposition and unique market positioning will soon crown MetAlert as a dominant player in its sector, commanding a significant market share and realizing substantial earnings while at it. “We believe certain key technologies addressing this global market have tremendous implications for cutting edge growth in health care. For example, imagine how valuable aggregated data collected by RoomMate and SmartSole plus combined with artificial intelligence will be for developing predictive scenarios and medicines to better the lives of tens of millions of people,” noted Mr. Bertagna. For more information, visit the company’s website at www.MetAlert.com. NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT